Hanall Biopharma Co., Ltd. (KRX:009420)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Manufacture and Sale of Pharmaceuticals	155.18B	138.94B	134.91B	110.00B	101.59B
Manufacture and Sale of Pharmaceuticals Growth	11.69%	2.99%	22.65%	8.27%	14.66%
Total	155.18B	138.94B	134.91B	110.00B	101.59B
Total Growth	11.69%	2.99%	22.65%	8.27%	14.66%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Export	7.80B	6.85B	70.63M	35.74M	16.07M
Export Growth	13.82%	9599.86%	97.61%	122.41%	-88.82%
South Korea	147.39B	132.09B	134.84B	109.96B	101.58B
South Korea Growth	11.58%	-2.04%	22.63%	8.25%	14.83%
Total	155.18B	138.94B	134.91B	110.00B	101.59B
Total Growth	11.69%	2.99%	22.65%	8.27%	14.66%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 24, 2026

Data Sources Report a data error